Inogen (NASDAQ:INGN) Posts Earnings Results, Misses Expectations By $0.42 EPS

Key Points

• Inogen significantly missed quarterly expectations: It reported a loss of $0.56 per share versus an expected loss of $0.14, while revenue of $77.2 million fell short of the $92.25 million consensus.
• Revenue from continuing operations declined 2.4% year over year. U.S. sales rose 3.8%, but international sales fell 9%, with weakness in Europe expected to persist into the fourth quarter.
• Inogen forecast fourth-quarter revenue of $65 million to $68 million and announced a cost-reduction plan targeting $20 million in annual savings by the end of 2027; it also reported $97.7 million in cash and no debt.

Inogen (NASDAQ:INGN - Get Free Report) issued its quarterly earnings results on Thursday. The medical technology company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.42), Zacks reports. The company had revenue of $77.19 million during the quarter, compared to the consensus estimate of $92.25 million. Inogen had a negative return on equity of 13.17% and a negative net margin of 6.94%.

Here are the key takeaways from Inogen's conference call:

• Third-quarter revenue from continuing operations was $77.2 million, down 2.4% year over year. U.S. sales grew 3.8%, but international sales fell 9% amid weaker European customer spending, a trend Inogen expects to continue into the fourth quarter.
• U.S. sales returned to year-over-year growth for the first time since late 2024, supported by distributor demand and new products. Portable oxygen concentrator unit volume increased nearly 6%, with new products contributing about 250 basis points of growth.
• Inogen completed the U.S. oxygen rental divestiture, with estimated cash consideration of up to $24.8 million expected in the first half of 2027. The company also announced a cost-reduction program targeting $20 million in annualized savings by the end of 2027; combined with the divestiture, savings are expected to exceed $40 million versus the pre-divestiture run rate.
• GAAP loss from continuing operations was $14.8 million, including a $10.6 million non-cash goodwill impairment, and operating cash flow was negative $4.5 million. Inogen expects a full-year adjusted net loss of $7 million to $8 million and fourth-quarter revenue of $65 million to $68 million.
• The company ended the quarter with $97.7 million in cash, cash equivalents, marketable securities, and restricted cash, with no debt outstanding. It increased its share repurchase authorization by $15 million to a total of $45 million.

Inogen Stock Performance

Shares of INGN traded down $0.74 during trading hours on Friday, hitting $6.03. 974,912 shares of the company were exchanged, compared to its average volume of 268,915. The firm has a fifty day simple moving average of $5.96 and a 200-day simple moving average of $6.23. Inogen has a one year low of $5.05 and a one year high of $7.67.

More Inogen News

Here are the key news stories impacting Inogen this week:

• Positive Sentiment: Inogen appointed Andy Reding as president and CEO and launched a $20 million cost-reduction program aimed at accelerating profitability. The savings could help improve results, though execution will be important. Inogen Announces Third Quarter 2026 Financial Results
• Neutral Sentiment: The company completed the sale of its U.S. oxygen rental business to Rotech on November 2. The divestiture changes the business mix, but the provided reports do not specify the sale’s financial impact. Leadership Transition and Cost-Reduction Program
• Neutral Sentiment: Trading in INGN was temporarily paused under a Limit Up-Limit Down (LULD) halt. The halt itself does not indicate the direction of the stock move.
• Negative Sentiment: Third-quarter revenue was $77.19 million versus analysts’ $92.25 million estimate, while loss per share was $0.56 versus an expected $0.14 loss—substantial misses that may weigh on investor confidence. Third-Quarter 2026 Financial Results
• Negative Sentiment: Inogen forecast FY 2026 revenue of $298 million–$301 million, far below the $356.4 million consensus. Its Q4 revenue outlook of $65 million–$68 million also trails the $84 million estimate, signaling a weaker near-term revenue outlook. Third-Quarter 2026 Financial Results

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a "sell (d-)" rating on shares of Inogen in a report on Tuesday. One research analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy".

Inogen Company Profile

Inogen, Inc is a medical technology company that develops, manufactures and markets portable oxygen concentrators for people who require long-term supplemental oxygen therapy. Its devices separate oxygen from ambient air and deliver concentrated oxygen without the need for traditional compressed-gas or liquid-oxygen tanks.

The company's product portfolio has included the Inogen One portable oxygen concentrator line, as well as stationary and related oxygen therapy products. These systems are designed to support mobility and independence for patients with chronic respiratory conditions while offering features such as rechargeable batteries, portability and various oxygen-delivery settings.

Founded in 2001 and headquartered in Goleta, California, Inogen sells its products through direct-to-consumer channels, health-care providers, distributors and other commercial partners.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.